Improved bioavailability from a spironolactone beta-cyclodextrin complex.
The relative bioavailabilty of spironolactone from a complex with beta-cyclodextrin has been evaluated. Capsules containing 100 mg micronised spironolactone powder were compared with 100 mg spironolactone beta-cyclodextrin complex in 8 healthy volunteers by a single dose, double blind, crossover pharmacokinetic study. Subjects were randomly allocated to each preparation and crossed over after 2 weeks. Relative bioavailability was assessed by the measurement of serum canrenone concentrations. The mean relative bioavailability of the spironolactone cyclodextrin complex, compared to the micronised spironolactone powder, was 233%. Statistical analysis (Wilcoxon signed rank test) revealed that this difference was significant with a mean area under the serum concentration time curve of 3.90 and 1.88 mg.h.l-1 for the complex and micronised spironolactone powder, respectively. Four of the volunteer also received a 100 mg spironolactone tablet (Aldactone) under identical conditions. Pharmacokinetic analysis revealed that the mean relative bioavailability of the spironolactone beta cyclodextrin complex and micronised powder when compared with spironolactone tablets (Aldactone) was 252% and 124%, respectively. There was no change in the canrenone elimination half lives of each subject.
Yusuff
N T
NT
Postgraduate School of Studies in Pharmaceutical Technology School of Pharmacy, University of Bradford.
York
P
P
Chrystyn
H
H
Bramley
P N
PN
Swallow
R D
RD
Tuladhar
B R
BR
Losowsky
M S
MS
D000328:Adult; D001682:Biological Availability; D003505:Cyclodextrins / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D011208:Powders; D013148:Spironolactone / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013607:Tablets; D047392:beta-Cyclodextrins
D003505:Cyclodextrins; D011208:Powders; D013607:Tablets; D047392:beta-Cyclodextrins; D013148:Spironolactone; C031215:betadex